Clinical trials: Intravenous Administration
Immunoglobulin Light Chain (AL) Amyloidosis
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by clonal bone marrow plasma…
- Trial name
- NCT06158854
- Testing
- ABBV-383 (Etentamig)
- Where
- 23 sites in United States, Australia and 4 more
- Volunteers
- 76 people
- Sponsor
- AbbVie
DM1, Myotonic Dystrophy
Global Study of Del-desiran for the Treatment of DM1
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy…
- Conditions
- DM1, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonia
- Trial name
- HARBOR (NCT06411288)
- Testing
- AOC 1001 (del-desiran)
- Where
- 34 sites in United States, Canada and 8 more
- Volunteers
- 159 people
- Sponsor
- Avidity Biosciences, Inc.
Rheumatoid Arthritis
Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis
The primary objective of the study is to assess the safety and efficacy of 2 dose groups (PDA001 versus vehicle control) in subjects with active rheumatoid Arthritis.
- Trial name
- NCT01261403
- Testing
- PDA001
- Where
- 16 sites in United States
- Volunteers
- 26 people
- Sponsor
- Celularity Incorporated
Metastatic Melanoma
A Study of Tasisulam in Treating Participants With Malignant Melanoma
The primary purpose of this study is to determine the objective response rate (complete and partial response) for participants who receive tasisulam after one prior systemic treatment for unresectable or metastatic melanoma.
- Trial name
- NCT00383292
- Testing
- tasisulam
- Where
- 13 sites in United States, Australia
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Cerebrovascular Accident
A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke
The primary objective of this study is to compare the efficacy of ONO-2506 versus placebo in neurological stroke outcome in patients with acute ischemic stroke.
- Trial name
- NCT00046761
- Testing
- ONO-2506
- Where
- 148 sites in United States, Canada
- Volunteers
- 1,320 people
- Sponsor
- Ono Pharma USA Inc
Rheumatoid Arthritis
Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis
This is a randomized double-blind comparative parallel group study of the efficacy and safety of tocilizumab biosimilar Complarate® and Actemra® in the treatment of patients with rheumatoid arthritis with moderate to high disease…
- Trial name
- NCT06475508
- Testing
- Complarate®, Actemra®
- Where
- 28 sites in Russia
- Volunteers
- 465 people
- Sponsor
- AO GENERIUM
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
This study was a multi-center, randomized, open-label, active comparator-controlled, parallel group study. The purpose of this Phase 3 study in PNH patients presenting with residual anemia despite treatment with anti-C5 antibody…
- Trial name
- APPLY-PNH (NCT04558918)
- Testing
- LNP023, Eculizumab, Ravulizumab
- Where
- 39 sites in United States, Brazil and 10 more
- Volunteers
- 97 people
- Sponsor
- Novartis Pharmaceuticals
Sarcoma, Soft Tissue
A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma
The purpose of this study is to assess how the body handles olaratumab when it is given with another drug called doxorubicin. The safety and tolerability of these drugs will be studied.
- Trial name
- NCT02326025
- Testing
- Olaratumab, Doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- Eli Lilly and Company
Colorectal Neoplasm, Iron Deficiency Anemia
Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate.
The main objective of this study is to evaluate the efficacy of intravenous iron sucrose in increasing preoperative haemoglobin values in patients with colo-rectal neoplasm and iron deficiency anemia, compared to the standard…
- Trial name
- NCT00199277
- Testing
- i.v. iron sucrose, Oral iron
- Where
- 5 sites in Spain
- Volunteers
- 150 people
- Sponsor
- J. Uriach and Company
Neoplasms
A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
This multi-center, open-label study will evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of vanucizumab as a single agent or in combination with atezolizumab in participants with locally advanced…
- Trial name
- NCT01688206
- Testing
- Atezolizumab [TECENTRIQ], Vanucizumab
- Where
- 14 sites in Belgium, France and 1 more
- Volunteers
- 132 people
- Sponsor
- Hoffmann-La Roche
Crohn's Disease
Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease
Human mesenchymal stem cells (MSCs), derived from healthy adult volunteer human donors, can be obtained from bone marrow donation and cultured in the laboratory.
- Trial name
- NCT00294112
- Testing
- Prochymal™ adult human mesenchymal stem cells, adult human mesenchymal stem cells
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Mesoblast, Inc.
Frailty Syndrome
Mesenchymal Stem Cells for The Treatment of Frailty Syndrome
The clinical study with UMC119-06-05 is designed to investigate the safety in patients with frailty syndrome. This will be a dose escalation, open label, single-center study in adult with frailty syndrome.
- Trial name
- NCT04914403
- Testing
- UMC119-06-05
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- Meridigen Biotech Co., Ltd.
Healthy
Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers
The purpose of this study is to evaluate the safety, immunogenicity and pharmacokinetics of RPH-104 after single intravenous and subcutaneous administration to healthy volunteers at different doses
- Trial name
- NCT07206043
- Testing
- RPH-104 80 mg, RPH-104 160 mg, RPH-104 320 mg
- Where
- Russia
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- R-Pharm International, LLC
Major Depressive Disorder
A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression
The purpose of this study is to assess the efficacy of esketamine compared with placebo in improving symptoms of depression in patients with treatment resistant depression.
- Trial name
- NCT01640080
- Testing
- Esketamine
- Where
- 9 sites in Belgium, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Janssen Research & Development, LLC
Healthy Volunteers
iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects
This is a Phase 1, double-blind, randomized, placebo-controlled study to investigate single and multiple intravenous infusions of improved cell-permeable nuclear import inhibitor (iCP NI) in healthy subjects.
- Trial name
- NCT05740280
- Testing
- iCP-NI
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Cellivery Therapeutics, Inc.
Melanoma
Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma
This is a multicenter, randomized, double-blind, parallel-group, 2 treatment group, repeated dose study to compare the PK, efficacy, safety, and immunogenicity of AVT32-DRL_PB (proposed Keytruda® biosimilar) versus Keytruda…
- Trial name
- NCT07475572
- Testing
- AVT32-DRL_PB, Keytruda
- Where
- Ukraine
- Volunteers
- 120 people
- Sponsor
- Alvotech Swiss AG
Myocardial Infarction
Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)
The objective of the present study is to establish the safety and efficacy of Prochymal® following first acute myocardial infarction.
- Trial name
- NCT00877903
- Testing
- Prochymal®
- Where
- 33 sites in United States, Canada
- Volunteers
- 220 people
- Sponsor
- Mesoblast, Inc.
Acute Myeloid Leukaemia
An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)
The purpose of the study is to assess how AZD1152 is absorbed or excreted in and out of the body in patients with Acute Myeloid Leukaemia (AML).
- Trial name
- NCT01019161
- Testing
- AZD1152, C14 AZD1152
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- AstraZeneca
Healthy
Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of GEn1E-1124
In this early phase clinical research study, the investigational drug will be administered to 64 healthy volunteers in a double-blind, placebo-controlled manner, at a one research center.
- Trial name
- NCT04728061
- Testing
- Gen1E-1124
- Where
- New Zealand
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GEn1E Lifesciences
Myotonic Dystrophy Type 1, DM1
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy…
- Conditions
- Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia
- Trial name
- HARBOR-OLE (NCT07008469)
- Testing
- Del-desiran (AOC 1001)
- Where
- 35 sites in United States, Canada and 8 more
- Volunteers
- 199 people
- Sponsor
- Avidity Biosciences, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.